A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer-Reference-Cited by-同舟云学术

A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer

Published:2014-01-09 Issue:3 Volume:143 Page:493-505
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Janni Wolfgang,Sarosiek Tomasz,Karaszewska Boguslawa,Pikiel Joanna,Staroslawska Elzbieta,Potemski Piotr,Salat Christoph,Brain Etienne,Caglevic Christian,Briggs Kathryn,DeSilvio Michelle,Marini Luca,Papadimitriou Christos

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-013-2828-z.pdf

Reference32 articles.

1. Hung MC, Lau YK (1999) Basic science of HER-2/neu: a review. Semin Oncol 26:51–59

2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182

3. Weigel MT, Dowsett M (2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer 17:R245–R262

4. Swain SM, Kim SB, Cortes J et al (2013) Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol 14:461–471

5. Blackwell KL, Burstein HJ, Sledge G, Stein S, Ellis C, Casey M, Baselga J, O’Shaughnessy J (2009) Updated survival analysis of a randomized study of lapatinib alone or in combination with tastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res 69:3

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Efficacy and Safety of Inetetamab and Pyrotinib in Combination with Vinorelbine for Second-line Therapy and Beyond in HER2-positive Metastatic Breast Cancer: A Single-institution Clinical Experience;Current Cancer Drug Targets;2023-10-24

2. Neoadjuvant pyrotinib plus trastuzumab and vinorelbine for HER2-positive locally advanced breast cancer patient who was initially resistant to HP therapy: a case report and literature review;Gland Surgery;2023-02

3. Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases;Annals of Medicine;2022-11-04

4. Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups;Frontiers in Oncology;2022-08-18

5. Anti-HER2 antibody prolongs overall survival disproportionally more than progression-free survival in HER2-Positive metastatic breast cancer patients;The Breast;2021-10